MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-06-2026
The Cooper Companies Interest Expense 2011-2026 | COO
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense The Cooper Companies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -16.4 M | -9.1 M | -14.9 M | 25 M | 23.1 M | 36.8 M | 68 M | 82.7 M | 33.4 M | 26.2 M | 18.1 M | 7.96 M | 9.17 M | 11.8 M | 17.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 82.7 M | -16.4 M | 21.3 M |
Quarterly Interest Expense The Cooper Companies
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.8 M | - | 1.6 M | -16.1 M | -2.7 M | - | -300 K | -2.8 M | -3.2 M | - | -6 M | 26.1 M | 26.1 M | 34.5 M | 17.1 M | 10.8 M | 6.4 M | 18.1 M | 5.6 M | 6.1 M | 11.6 M | 30.1 M | 5.7 M | 12.8 M | 18.2 M | 53.3 M | 16.7 M | 18.5 M | 18.4 M | 59.9 M | 22.8 M | 18.7 M | 7.3 M | 23.3 M | 8.3 M | 7.7 M | 5.3 M | 20.9 M | 8 M | 7.6 M | 3.94 M | 13.3 M | 4.69 M | 4.69 M | 1.66 M | 4.71 M | 1.5 M | 1.56 M | 2.57 M | 7.27 M | 2.26 M | 2.44 M | 3.66 M | 9.05 M | 2.32 M | 3.07 M | 6.95 M | 14.4 M | 3.22 M | 4.27 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 59.9 M | -16.1 M | 10.5 M |
Interest Expense of other stocks in the Medical instruments industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AtriCure
ATRC
|
683 K | $ 29.85 | 1.05 % | $ 1.43 B |  USA |
 |
AngioDynamics
ANGO
|
4.94 M | $ 10.6 | -1.03 % | $ 433 M | USA |
 |
Atrion Corporation
ATRI
|
149 | - | - | $ 810 M | USA |
 |
Harvard Bioscience
HBIO
|
-227 K | $ 0.47 | -4.15 % | $ 19.9 M | USA |
 |
Alcon
ALC
|
204 M | $ 77.32 | -1.5 % | $ 40.4 B |  Schweiz |
 |
ICU Medical
ICUI
|
93.3 M | $ 125.85 | -2.28 % | $ 3.1 B | USA |
 |
InfuSystem Holdings
INFU
|
1.4 M | $ 9.31 | -0.85 % | $ 192 M | USA |
 |
iRhythm Technologies
IRTC
|
5.44 M | $ 113.0 | -1.46 % | $ 3.62 B | USA |
 |
Glaukos Corporation
GKOS
|
13.6 M | $ 97.02 | -0.79 % | $ 4.7 B | USA |
 |
Becton, Dickinson and Company
BDX
|
613 M | $ 159.36 | -0.17 % | $ 45.8 B | USA |
 |
Haemonetics Corporation
HAE
|
-9.75 M | $ 59.92 | 0.72 % | $ 3.02 B | USA |
 |
electroCore
ECOR
|
6.3 M | $ 6.14 | -3.0 % | $ 33.9 K | USA |
 |
Masimo Corporation
MASI
|
300 K | $ 175.49 | -0.01 % | $ 9.35 B | USA |
 |
Isoray
ISR
|
2 K | - | 0.03 % | $ 108 M | USA |
 |
Predictive Oncology
POAI
|
3 | - | - | $ 31.1 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
-26 K | $ 11.56 | -2.12 % | $ 28 M | USA |
 |
Repro Med Systems
KRMD
|
9.91 K | $ 4.28 | -0.7 % | $ 198 M | USA |
 |
Baxter International
BAX
|
290 M | $ 17.4 | -3.36 % | $ 8.93 B | USA |
 |
BioLife Solutions
BLFS
|
497 K | $ 18.36 | 1.16 % | $ 846 M | USA |
 |
Nephros
NEPH
|
2 K | $ 3.5 | -7.89 % | $ 36.4 M | USA |
 |
ResMed
RMD
|
3.2 M | $ 230.84 | -0.68 % | $ 33.7 B | USA |
 |
Retractable Technologies
RVP
|
227 K | $ 0.71 | 2.62 % | $ 21.3 M | USA |
 |
Merit Medical Systems
MMSI
|
-2.39 M | $ 69.95 | 2.61 % | $ 4.14 B | USA |
 |
Envista Holdings Corporation
NVST
|
-2.3 M | $ 24.61 | -3.26 % | $ 4.13 B | USA |
 |
STAAR Surgical Company
STAA
|
2.25 M | $ 18.84 | 2.45 % | $ 934 M | USA |
 |
Stereotaxis
STXS
|
2 K | $ 1.89 | 0.27 % | $ 172 M | USA |
 |
Teleflex Incorporated
TFX
|
57 M | $ 107.32 | -0.87 % | $ 4.79 B | USA |
 |
OraSure Technologies
OSUR
|
229 K | $ 2.97 | -3.88 % | $ 218 M | USA |
 |
LeMaitre Vascular
LMAT
|
5.18 M | $ 108.06 | 1.43 % | $ 2.45 B | USA |
 |
Utah Medical Products
UTMD
|
256 K | $ 63.28 | 1.02 % | $ 230 M | USA |
 |
Pro-Dex
PDEX
|
533 K | $ 48.46 | 3.5 % | $ 159 M | USA |
 |
Microbot Medical
MBOT
|
2 K | $ 2.69 | -1.47 % | $ 27.4 M |  Israel |
 |
West Pharmaceutical Services
WST
|
-1 M | $ 235.46 | 1.89 % | $ 17 B | USA |
 |
Repligen Corporation
RGEN
|
8.12 M | $ 114.2 | 0.39 % | $ 6.36 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
24 M | $ 11.54 | -2.2 % | $ 2.3 B | USA |
 |
Pulse Biosciences
PLSE
|
-52 K | $ 21.57 | 1.27 % | $ 1.45 B | USA |
 |
STERIS plc
STE
|
8.4 M | $ 214.57 | 1.05 % | $ 21.2 B | USA |
 |
Milestone Scientific
MLSS
|
60.3 K | $ 0.28 | -3.75 % | $ 22.3 M | USA |